NeoGenomics, Inc. (NEO) P/E Ratio History
Deep ValueTrading at -3.5x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2012–2021
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, NeoGenomics, Inc. (NEO) trades at a price-to-earnings ratio of -3.5x, with a stock price of $14.50 and trailing twelve-month earnings per share of $-3.84.
The current P/E is 103% below its 5-year average of 113.0x. Over the past five years, NEO's P/E has ranged from a low of 14.1x to a high of 538.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, NEO trades at a 115% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
Relative to the broader market, NEO trades at a notable discount to the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NEO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NEO Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
NEO P/E vs Peers
Clinical and Specialty Lab Testing peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $3B | 135.9 | - | +109% | |
| $23B | 27.1 | - | +18% | |
| $24B | 24.3 | - | +14% | |
| $7B | 55.7 | 3.33Best | +311% | |
| $2B | 47.4 | 7.07 | +14% | |
| $226M | 6.3Lowest | - | +338%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
NEO Historical P/E Data (2012–2021)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2021 Q3 | - | $48.24 | $1.80 | 26.8x | -76% |
| FY2021 Q2 | Jun 30 2021 | $45.17 | $2.75 | 16.4x | -85% |
| FY2020 Q4 | - | $53.84 | $0.10 | 538.4x | +389% |
| FY2020 Q1 | - | $27.61 | $0.17 | 162.4x | +48% |
| FY2019 Q4 | - | $29.25 | $0.37 | 79.1x | -28% |
| FY2019 Q3 | Sep 30 2019 | $19.12 | $0.09 | 217.3x | +97% |
| FY2019 Q2 | Jun 30 2019 | $21.94 | $0.09 | 249.3x | +127% |
| FY2018 Q4 | Dec 31 2018 | $12.61 | $0.14 | 92.0x | -16% |
| FY2018 Q3 | Sep 30 2018 | $15.35 | $0.43 | 35.8x | -67% |
| FY2018 Q2 | Jun 30 2018 | $13.11 | $0.06 | 222.2x | +102% |
| FY2018 Q1 | Mar 31 2018 | $8.16 | $0.11 | 73.8x | -33% |
| FY2015 Q1 | - | $4.67 | $0.02 | 239.5x | +118% |
| FY2014 Q4 | Dec 31 2014 | $4.17 | $0.09 | 45.3x | -59% |
| FY2014 Q3 | - | $5.21 | $0.11 | 48.0x | -56% |
| FY2014 Q2 | Jun 30 2014 | $3.32 | $0.23 | 14.1x | -87% |
| FY2014 Q1 | Mar 31 2014 | $3.47 | $0.23 | 14.8x | -87% |
| FY2013 Q4 | - | $3.62 | $0.23 | 16.0x | -85% |
| FY2013 Q3 | Sep 30 2013 | $3.00 | $0.11 | 26.3x | -76% |
| FY2012 Q3 | Sep 30 2012 | $3.01 | $0.02 | 128.1x | +16% |
| FY2012 Q2 | Jun 30 2012 | $1.70 | $0.12 | 14.5x | -87% |
| FY2012 Q1 | Mar 31 2012 | $1.69 | $0.03 | 51.2x | -53% |
Average P/E for displayed period: 110.1x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NEO — Frequently Asked Questions
Quick answers to the most common questions about buying NEO stock.
What is NEO's P/E ratio?
NeoGenomics, Inc. (NEO) trailing twelve-month P/E ratio is -3.5x, based on TTM diluted EPS of $-3.84. The 5-year average P/E is 113.0x and the historical range spans 14.1x to 538.4x.
Is NEO stock overvalued or undervalued?
NEO trades at -3.5x P/E, below its 5-year average of 113.0x. At the 0th percentile of its historical range (14.1x–538.4x), the stock is priced at a discount to its own history.
Is NEO stock expensive?
No, NEO is not expensive on a historical basis. The current P/E of -3.5x is below the 5-year average of 113.0x and sits at the 0th percentile of its valuation range.
What is NEO's historical P/E range?
Over the past 5 years, NEO's P/E ratio has ranged from 14.1x to 538.4x, with a median of 73.8x and an average of 113.0x. The current P/E of -3.5x places the stock at the 0th percentile of this range. Full historical data spans 2012–2021.
How does NEO's P/E compare to the S&P 500?
NEO trades at -3.5x P/E versus the S&P 500 median of 25.9x. The 114% discount to the market suggests lower growth expectations or perceived higher risk.
How does NEO's valuation compare to Healthcare peers?
NeoGenomics, Inc. P/E of -3.5x compares to the Healthcare sector median of 23.4x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is NEO's PEG ratio?
NEO PEG ratio is N/A, based on a P/E of -3.5x and EPS growth of -35.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is NEO's earnings yield?
NEO earnings yield is N/A, the inverse of its -3.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.